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pared to active controls. Meta-analyses did not find a dif-
ference between rofecoxib and celecoxib in broad safety
measures.
CONCLUSION: Caveats to this analysis include the po-
tential for selection and instrument bias. The two coxibs
show comparable overall efficacy and safety. However,
caution is advised in applying the results of aggregate anal-
yses at the individual patient level. Since the safety profiles
for the coxibs are somewhat different, arthritis treatment
should be individualized based on patient co-morbidities.
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OBJECTIVES: To measure quality of life and health-care
utilization related to osteoarthritis and to understand the
relationship among different parameters.
METHODS: 245 patients with osteoarthrosis (176 fe-
male) of mean age 64 years were recruited within a mus-
culoskeletal study in both primary care and rheumatol-
ogy outpatient settings in Hungary in 1999 and 2000.
Patients filled in both the generic EQ-5D quality-of-life
questionnaire and the disease-specific WOMAC ques-
tionnaire and reported resource utilization. Mean quality-
of-life and health-care-utilization values were reported
and correlation coefficients between different measure-
ments were analyzed.
RESULTS: Average EQ-5D index, EQ-5Dvas, WOMAC
(pain (A), stiffness (B), physical function (C)) scores were
0.42, 49.18, 9.28, 3.87, 36.32 respectively. Average an-
nual number of physiotherapy and spa treatment sessions
were 33.32 and 9.88, respectively. Average number of
GP and specialist visits were 31.4 and 8.54 annually. Pa-
tients spent a mean of nine days in hospital and they
spent 12.5 days in bed due to osteoarthritis. Active pa-
tients spent a mean of 6.7 days on sick leave. Statistically
significant correlation was observed between the follow-
ing: EQ-5D index and EQ-5Dvas; EQ-5D index and
WOMAC C; EQ-5Dvas and WOMAC C; days in bed
and EQ-5D index; days in bed and EQ-5Dvas; days in
bed and WOMAC C. Corresponding correlation coeffi-
cients were: 0.35; 0.59; 0.33; 0.35; 0.17; 0.24; re-
spectively (p  .01).
CONCLUSIONS: Results showed that osteoarthritis
leads to substantial loss in quality of life, important direct
medical costs, and substantial productivity loss among
active patients.
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OBJECTIVE: In order to assess the impact of interven-
tion programs to be implemented, a baseline assessment
of the burden of illness for arthritis is needed. Nearly one
third of Philadelphians receive their medical care through
Medicaid. To be representative of the population we
serve, we therefore set out to measure the incidence and
impact of arthritis in an inner city, Medicaid managed-
care population.
METHODS: We identified members continuously en-
rolled (per HEDIS definitions) during 1999 with paid
claims reflecting diagnoses indicative of arthritis. Primary
through quaternary diagnoses for arthritis (ICD-9CM
codes 095.6, 095.7, 095.8, 099.3, 136.1, 274, 277.2, 287.0,
344.6, 353.0, 354.0, 355.5, 357.1, 390, 391, 437.4,
443.0, 446, 447.6, 696.0, 710–716, 719.0, 719.2–719.9,
720–721, 725–727, 728.0–728.3, 728.6–728.9, 729.0–
729.1, and 729.4) were used to determine incidence. To-
tal amounts paid per claim were tallied. Arthritis-related
drugs were those defined as AHFS classes 12:20.00,
28:08.04, 28:08.08 and unclassified arthritis related agents.
Members’ demographic data was also obtained.
RESULTS: From a cohort of 73,948 members, we identi-
fied 8197 (11.1%) individuals with a medical claim for
arthritis. Females comprised 77.0% (1744) of these mem-
bers, greater than the norm for this population (p  .05).
The average age was 53.8 years. This population with ar-
thritis was composed of 46.8% African-Americans,
23.2% Caucasians, 23.7% Latinos, and 3.0% Asian-
Americans. Medical claims and arthritis-related drug
costs for this population totaled $5,328,406 ($650 per
identified member).
CONCLUSION: Effects of interventions cannot be mea-
sured until baseline information is assessed. It is hoped
that along with the data gathered here, an intervention
can be implemented citywide, the effects of which can be
measured. The diversity of Philadelphia’s population
should allow for differences that might exist among eth-
nic groups to be demonstrated. Managed care payers are
also responsible for drug expenditures. The costs for
some of these products are presented herein.
PAO4
THE COST-EFFECTIVENESS OF CELECOXIB 
COMPARED TO DICLOFENAC IN PATIENTS 
WITH RHEUMATOID ARTHRITIS IN POLAND
Orlewska E
Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: to estimate the cost-effectiveness of cele-
coxib 0,2 g bid vs. diclofenac 75 mg bid in rheumatoid
arthritis (RA) patients in Poland and to identify whether
and to what extent celecoxib represents good use of
health-service resources.
METHODS: A decision analytic model in the Polish
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health-care context was developed, based on the use of
epidemiological and clinical data obtained from literature
and local data on health-care resource utilisation and
health-care unit costs. Only direct medical costs were
analysed. The perspective of the health-care payers (sick
funds and patients) and a time horizon of six months
were taken. The target population was RA patients aged
55, with an average risk of 9-12 points using Fries calcu-
lator. Effectiveness was expressed in terms of the number
of patients free of symptomatic ulcer. On this basis, saved
lives and life years gained were calculated. The cost-effec-
tiveness threshold, calculated on the basis of one-year
haemodialysis treatment cost of 60000 PLN (1 USD  4
PLN), was determined to assess whether celecoxib ther-
apy should be adopted.
RESULTS: The cost-effectiveness analysis showed that
celecoxib treatment of RA patients gives additional life
years for extra costs. The cost per symptomatic ulcer or
death averted for celecoxib, compared with diclofenac,
were 20431 to 20676 and 600887 to 608887 PLN re-
spectively. In the study population, 1 LYG costs 32300
PLN and is below the suggested threshold. One-way sen-
sitivity analysis showed that results are sensitive to
changes in price of celecoxib and the probability of
NSAID-induced GI events. The threshold analysis sug-
gests that celecoxib would be the dominant therapy if its
cost or daily dose were to decrease by 60%.
CONCLUSION: The treatment with celecoxib vs. diclo-
fenac 75 SR in RA may be cost-effective in Poland. Cost/
LYG was below the suggested cost-effectiveness thresh-
old, if avoidance of 1 death generates more than 10 LY.
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OBJECTIVES: To analyze direct medical costs for man-
agement of nonsteroidal anti-inflammatory drug (NSAID)
induced gastrointestinal adverse events, with or without
gastroprotective agents, in patients with osteoarthritis or
rheumatoid arthritis from the perspective of a public
health organization in Hong Kong.
METHODS: A decision-tree was used to analyze, over
six months, the resource utilization associated with five
treatment alternatives: a cyclooxygenase-2 (COX-2) in-
hibitor (celecoxib); NSAID only; NSAID plus H2-recep-
tor antagonist (H2RA); NSAID plus misoprostol, and
NSAID plus proton-pump inhibitor (PPI). Each alterna-
tive could lead to five possible outcomes: no gastrointes-
tinal (GI) toxicity; GI discomforts; symptomatic ulcer;
anaemia with occult bleeding, and serious GI complica-
tions. The probabilities of GI adverse events were taken
from the literature. Resource utilization for all outcomes,
except for anaemia with occult bleeding, was retrieved
from the database of a major public hospital in Hong
Kong. The resource utilization for anaemia with occult
bleeding was gathered by expert interview. A one-way
sensitivity analysis was performed to assess the relative
impact of patients’ underlying GI risk score, based on the
modified version of the Fries risk calculator, on the ex-
pected value of each alternative.
RESULTS: The costs associated with the alternatives, per
base case analysis, were as follows: NSAID plus H2RA
HK$966 (1USD7.8HKD); celecoxib HK$1189; NSAID
alone HK$1293; NSAID plus misoprostol HK$1523,
and, NSAID plus PPI HK$2327. One-way sensitivity
analysis showed that the cost of NSAID plus H2RA was
the lowest in patients with a GI risk score below 15-16,
and the cost of celecoxib therapy was the lowest when
the GI risk score was greater than or equal to 15-16.
CONCLUSION: Based on the decision-tree analysis of
the data obtained, NSAID plus H2RA is the least costly
regimen in patients with low GI risk score and celecoxib
is the least costly alternative in patients with intermediate
to high GI risk score in Hong Kong.
PAO6
COST-EFFECTIVENESS ANALYSIS OF 
USING CELECOXIB IN THE TREATMENT 
OF OSTEOARTHRITIS
Soto J1, Rejas J2
1Pharmacia S.A, Madrid, Spain; 2Pfizer S.A, Alcobendas 
(Madrid), Spain
OBJECTIVE: To ascertain the efficiency of Celecoxib
versus non-steroidal anti-inflammatory drugs (NSAID) in
treating osteoarthritis.
METHODS: The study was performed using a decision
analytic model that represents the daily medical practice
in our country by running two hypothetical cohorts of
10,000 patients either with Celecoxib or any NSAID.
The simple decision tree of the model has two different
branches: a) Celecoxib, and b) NSAID, divided into
NSAID  gastroprotective agents and NSAID alone.
Each branch may follow different clinical evolutions: no
adverse reactions; appearance of gastro-intestinal (G-I)
discomfort; symptomatic ulcers, and severe G-I complica-
tions followed by death. The probabilities for the devel-
opment of these adverse events have been obtained from
medical literature, national statistics (life expectancy) and
a local expert panel. The effectiveness unit chosen was
life-years gained after the use of both options. Only direct
costs were included (medications, additional examina-
tions and analytical tests, days of hospitalization, treat-
ment of ulcers and G-I complications). The time horizon
was six months and the perspective selected was the
Spanish National Health Service (NHS).
RESULTS: The total cost of the cohort treated with Cele-
coxib was 570,456,110 pesetas (US $2,955,731) while
in the cohort treated with NSAIDs this amounted to
340,328,814 pesetas (US $1,763,361). In the Celecoxib
